Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Pharma & Biotech

Entyvio pediatric filing puts Takeda at the centre of the next IBD treatment debate

Find out how Takeda’s pediatric Entyvio review could change biologic treatment choices in ulcerative colitis and Crohn’s disease.

Read More
Representative image: A PET/CT imaging suite illustrates how Pentixapharm’s [68Ga]Ga-PentixaFor Phase 3 PANDA study could reshape primary aldosteronism diagnostics and cardiovascular precision medicine.
Medical Devices & Diagnostics

Why a CXCR4 PET/CT tracer could become Pentixapharm’s most important cardiovascular asset

See why Pentixapharm’s Phase 3 CXCR4 PET/CT push could challenge a stubborn diagnostic bottleneck in primary aldosteronism.

Read More
Representative image: A clinician reviews spinal imaging for chronic low back pain as Vertanical’s Exilby approval highlights the growing push for regulated non-opioid pain treatments in Europe.
Pharma & Biotech

Vertanical’s Exilby approval puts cannabis-derived pain drugs under a brighter spotlight

Exilby’s German approval gives chronic pain medicine a rare non-opioid test case. Can Vertanical convert data into adoption?

Read More
Representative image: GSK’s $10.6 billion Nuvalent deal puts precision lung cancer therapies in focus as Big Pharma races to secure late-stage oncology assets.
Pharma & Biotech

Why GSK is paying $10.6bn for Nuvalent as targeted lung cancer drugs near FDA decisions

GSK is betting $10.6B on Nuvalent’s lung cancer drugs. The payoff now depends on FDA decisions, labels and oncology launch execution.

Read More
Representative image of oncology researchers reviewing molecular data in a biotechnology lab, reflecting Johnson & Johnson’s Firefly Bio deal and the race to advance degrader antibody conjugates for hard-to-treat solid tumors.
Pharma & Biotech

Why Johnson & Johnson is paying $1bn for Firefly Bio’s cancer drug platform

Johnson & Johnson is chasing the next cancer drug platform. Firefly Bio adds promise, but clinical proof remains the real test.

Read More
Xenix Medical’s expandable lumbar fusion push now faces the real commercial trial
Medical Devices & Diagnostics

Xenix Medical’s Lux system targets a key pain point in lumbar fusion surgery

Lux gives Xenix Medical a lumbar fusion opening. Read why adoption, evidence and surgeon workflow now matter most.

Read More
Representative image of AI-enabled liver disease research, reflecting how insitro’s CTRO-1013 MASH candidate is being studied for anti-fibrotic signals beyond liver fat reduction.
Pharma & Biotech

insitro’s MASH candidate adds a fibrosis signal, but human proof remains the real test

AI met MASH fibrosis, but mouse data are only the first test. See why insitro’s CTRO-1013 signal matters now.

Read More
Representative image of an intensive care unit ventilator setup, highlighting how diaphragm stimulation devices such as Lungpacer Medical’s AeroPace System could help hospitals support faster ventilator weaning in critically ill patients.
Medical Devices & Diagnostics

Can Lungpacer Medical’s AeroPace System change the economics of ventilator recovery?

AeroPace moves into East Coast ICU care as hospitals test whether diaphragm stimulation can shorten ventilator recovery. Read the analysis.

Read More
Representative image of RNAi drug discovery research in a biotechnology laboratory. City Therapeutics’ $99.5 million Series B financing puts next-generation RNA interference therapies, including CITY-FXI and CITY-RBP4, in sharper focus as the field expands beyond liver-targeted medicines.
Pharma & Biotech

City Therapeutics raises $99.5m as CITY-FXI and CITY-RBP4 head toward key tests

City Therapeutics has fresh capital, but RNAi’s next test is tissue delivery. See why CITY-FXI and CITY-RBP4 matter now.

Read More
Representative image: A pediatric neurology research setting highlights the clinical focus on tralesinidase alfa, enzyme replacement therapy, and long-term treatment advances for Sanfilippo syndrome type B.
Pharma & Biotech

Could Spruce Biosciences finally change the Sanfilippo syndrome type B treatment landscape?

Spruce Biosciences’ MPS IIIB data raise a pivotal question: can tralesinidase alfa turn biomarker gains into disease-changing therapy?

Read More